To evaluate the utility of different outcome measures to monitor dose adjustment of intravenous immunoglobulin (IVIg) therapy in patients with chronic inflammatory neuropathy (CIN). We assessed the adjustment of IVIg maintenance therapy in 20 patients (10 CIDP and 10 MMN) by regularly monitoring grip strength (GS) using a Martin Vigorimeter, RODS, and quality of life using the SF‐36 questionnaire. These measures were regularly performed by the patient at home. We also assessed the extended MRC sumscore (eMRC sumscore) at each outpatient visit for IVIg infusion. We also enrolled 30 healthy controls to measure any possible training effect of GS with time and to analyze random fluctuation of GS. Clinically relevant change was detected by eMRC sumscore in 14 (93%) patients, by RODS in 11 (73%) patients, and by GS in 8 (53%) patients. Early sensitivity was greatest for RODS (73%), followed by GS (53%), and eMRC sumscore (27%). This differed from CIDP, with an early change in RODS in 100% of patients, and MMN with an early change in GS in 75%. None of the outcome measures alone was sufficient to detect clinically significant changes in all patients. Home monitoring of outcome measures objectively assisted clinical decision during individualization of IVIg treatment. We recommend a multimodal approach using different outcome measures to monitor the individual patient with CIN.

中文翻译：

---

慢性炎症性神经病变患者静脉注射免疫球蛋白维持治疗的家庭监测。

评估不同结局指标在慢性炎症性神经病 (CIN) 患者中监测静脉免疫球蛋白 (IVIg) 治疗剂量调整的效用。我们通过使用 Martin Vigorimeter、RODS 和使用 SF-36 问卷定期监测握力 (GS) 和生活质量来评估 20 名患者（10 个 CIDP 和 10 个 MMN）对 IVIg 维持治疗的调整。这些措施由患者在家中定期进行。我们还在每次门诊就诊时评估了 IVIg 输注的扩展 MRC sumscore (eMRC sumscore)。我们还招募了 30 名健康对照，以测量 GS 随着时间的任何可能的训练效果并分析 GS 的随机波动。通过 eMRC sumscore 检测到 14 名（93%）患者的临床相关变化，11 名（73%）患者的 RODS 和 8 名（53%）患者的 GS 检测到临床相关变化。RODS 的早期敏感性最高 (73%)，其次是 GS (53%) 和 eMRC sumscore (27%)。这与 CIDP 不同，100% 的患者 RODS 发生早期变化，而 MMN 中 75% 的患者发生 GS 早期变化。单独的结果测量均不足以检测所有患者的临床显着变化。在 IVIg 治疗的个体化过程中，对结果测量的家庭监测客观地辅助了临床决策。我们推荐使用不同结果测量的多模式方法来监测个体 CIN 患者。在 IVIg 治疗的个体化过程中，对结果测量的家庭监测客观地辅助了临床决策。我们推荐使用不同结果测量的多模式方法来监测个体 CIN 患者。在 IVIg 治疗的个体化过程中，对结果测量的家庭监测客观地辅助了临床决策。我们推荐使用不同结果测量的多模式方法来监测个体 CIN 患者。